Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
Yahoo Finance
Phase 3b trial results for SIMTRIYO® (centanafadine) show consistent improvements in ADHD symptoms, anxiety, and related features in adults with ADHD and comorbid anxiety disorders. The findings were presented at Psych Congress 2026, highlighting the drug's potential efficacy across multiple domains. These results suggest SIMTRIYO® may offer a comprehensive treatment option for patients with both ADHD and anxiety.
All articles from 19 September 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.